Payment overview · 2025
General Payments
$102.53
5 reported records · 3 companies
Healthcare provider profile · identity verified
Vijitha Prasad, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · SWAINSBORO, GA · NPI 1275520090
Verified facts
What the public records show
CMS Open Payments records show Vijitha Prasad, M.D. received $102.53 in general payments during 2025 across 5 reported records.
GlaxoSmithKline, LLC. accounted for 70.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.29 | 70.5% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.75 | 15.4% | 1 | 2025 |
| Ceribell, Inc. | Unresolved — no canonical attribution shown | $14.49 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $102.53 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.29 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| POCKET EEG DEVICE Normalized: pocket eeg device |
Device | Ceribell, Inc. | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 168 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
168 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1161 | 232 |
| Pantoprazole Sodium | Pantoprazole Sodium | 890 | 214 |
| Atorvastatin Calcium | Atorvastatin Calcium | 828 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 760 | 192 |
| Furosemide | Furosemide | 733 | 154 |
| Tramadol Hcl | Tramadol Hcl | 682 | 156 |
| Potassium Chloride | Potassium Chloride | 680 | 148 |
| Losartan Potassium | Losartan Potassium | 637 | 129 |
| Famotidine | Famotidine | 548 | 106 |
| Gabapentin | Gabapentin | 544 | 135 |
| Omeprazole | Omeprazole | 520 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 505 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 472 | 86 |
| Meloxicam | Meloxicam | 446 | 124 |
| Eliquis | Apixaban | 443 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 440 | 112 |
| Glimepiride | Glimepiride | 425 | 89 |
| Donepezil Hcl | Donepezil Hcl | 391 | 48 |
| Carvedilol | Carvedilol | 370 | 67 |
| Tizanidine Hcl | Tizanidine Hcl | 369 | 101 |
| Methylprednisolone | Methylprednisolone | 327 | 225 |
| Clonazepam | Clonazepam | 323 | 79 |
| Metformin Hcl | Metformin Hcl | 322 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 322 | 75 |
| Buspirone Hcl | Buspirone Hcl | 312 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 307 | 128 |
| Duloxetine Hcl | Duloxetine Hcl | 305 | 46 |
| Sertraline Hcl | Sertraline Hcl | 301 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 289 | 112 |
| Prednisone | Prednisone | 289 | 182 |
| Simvastatin | Simvastatin | 285 | 75 |
| Azithromycin | Azithromycin | 276 | 211 |
| Alprazolam | Alprazolam | 272 | 52 |
| Levofloxacin | Levofloxacin | 271 | 205 |
| Montelukast Sodium | Montelukast Sodium | 256 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 253 | 41 |
| Lorazepam | Lorazepam | 246 | 52 |
| Pregabalin | Pregabalin | 226 | 53 |
| Allopurinol | Allopurinol | 223 | 62 |
| Ropinirole Hcl | Ropinirole Hcl | 215 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 197 | 49 |
| Mounjaro | Tirzepatide | 195 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 194 | 53 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 31 |
| Celecoxib | Celecoxib | 182 | 51 |
| Ozempic | Semaglutide | 182 | 40 |
| Spironolactone | Spironolactone | 182 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 180 | 52 |
| Trazodone Hcl | Trazodone Hcl | 176 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 47 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 168 | 52 |
| Quetiapine Fumarate | Quetiapine Fumarate | 165 | 26 |
| Lisinopril | Lisinopril | 164 | 47 |
| Sucralfate | Sucralfate | 161 | 37 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 154 | 29 |
| Bumetanide | Bumetanide | 146 | 33 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 144 | 31 |
| Risperidone | Risperidone | 141 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 138 | 34 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 137 | 28 |
| Fluconazole | Fluconazole | 135 | 97 |
| Memantine Hcl | Memantine Hcl | 133 | 11 |
| Bupropion Xl | Bupropion Hcl | 122 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 119 | 70 |
| Oxybutynin Chloride | Oxybutynin Chloride | 118 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 114 | 64 |
| Colchicine | Colchicine | 113 | 20 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 113 | 23 |
| Glipizide Er | Glipizide | 112 | 33 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 111 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 32 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 109 | 27 |
| Mirtazapine | Mirtazapine | 106 | 20 |
| Estradiol | Estradiol | 103 | 39 |
| Meclizine Hcl | Meclizine Hcl | 102 | 30 |
| Cefdinir | Cefdinir | 96 | 74 |
| Temazepam | Temazepam | 96 | 22 |
| Divalproex Sodium | Divalproex Sodium | 95 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 91 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 90 | 38 |
| Lamotrigine | Lamotrigine | 86 | 26 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 83 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 32 |
| Linzess | Linaclotide | 82 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 79 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 79 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 77 | 14 |
| Valsartan | Valsartan | 74 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 73 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 22 |
| Atenolol | Atenolol | 69 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 68 | 38 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 68 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 68 | 19 |
| Fenofibrate | Fenofibrate | 68 | 16 |
| Finasteride | Finasteride | 66 | 16 |
| Primidone | Primidone | 66 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 14 |
| Mupirocin | Mupirocin | 64 | 50 |
| Methenamine Hippurate | Methenamine Hippurate | 60 | 14 |
| Ondansetron Odt | Ondansetron | 60 | 30 |
| Trulicity | Dulaglutide | 60 | 13 |
| Ezetimibe | Ezetimibe | 57 | 17 |
| Nystatin | Nystatin | 55 | 28 |
| Clonidine Hcl | Clonidine Hcl | 54 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Roflumilast | Roflumilast | 53 | suppressed |
| Silodosin | Silodosin | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 51 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 13 |
| Aripiprazole | Aripiprazole | 50 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 20 |
| Olanzapine | Olanzapine | 47 | suppressed |
| Xarelto | Rivaroxaban | 47 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 24 |
| Methotrexate | Methotrexate Sodium | 46 | 13 |
| Midodrine Hcl | Midodrine Hcl | 46 | 17 |
| Warfarin Sodium | Warfarin Sodium | 46 | 15 |
| Clonidine | Clonidine | 45 | suppressed |
| Cephalexin | Cephalexin | 44 | 38 |
| Ventolin Hfa | Albuterol Sulfate | 44 | 26 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 44 | 16 |
| Entresto | Sacubitril/Valsartan | 43 | 14 |
| Latanoprost | Latanoprost | 43 | suppressed |
| Rexulti | Brexpiprazole | 43 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 42 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 41 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 41 | suppressed |
| Nifedipine Er | Nifedipine | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 38 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Diazepam | Diazepam | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 33 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Ziprasidone Hcl | Ziprasidone Hcl | 38 | suppressed |
| Amoxicillin | Amoxicillin | 35 | 19 |
| Acyclovir | Acyclovir | 34 | 15 |
| Ibuprofen | Ibuprofen | 34 | 15 |
| Lovastatin | Lovastatin | 34 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 33 | 21 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Lactulose | Lactulose | 32 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 29 | suppressed |
| Dutasteride | Dutasteride | 28 | 11 |
| Constulose | Lactulose | 27 | suppressed |
| Dexamethasone | Dexamethasone | 27 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | suppressed |
| Irbesartan | Irbesartan | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Folic Acid | Folic Acid | 24 | suppressed |
| Humulin R | Insulin Regular, Human | 24 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 23 | suppressed |
| Methadone Hcl | Methadone Hcl | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Calcitriol | Calcitriol | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 17 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Mitigare | Colchicine | 17 | suppressed |
| Piroxicam | Piroxicam | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | 11 |
| Lidocaine | Lidocaine | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Terconazole | Terconazole | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Enbrel Sureclick | Etanercept | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 11 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Sure Comfort Pen Needle | Pen Needle, Diabetic | 11 | 11 |
| Torsemide | Torsemide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $102.53 · 5 records | GlaxoSmithKline, LLC. | FARXIGA, POCKET EEG DEVICE, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error